These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25641150)

  • 1. [Successful treatment with melphalan, dexamethasone and thalidomide for relapsed idiopathic light chain deposit disease: a case report and literature review].
    Duan M; Wen Y
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jan; 36(1):60-2. PubMed ID: 25641150
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
    Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA
    Med Oncol; 2002; 19(4):219-26. PubMed ID: 12512915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
    Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
    Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
    Asou N; Izuno Y; Okubo T; Ide K; Ueno H; Kawakita M; Mitsuya H; Hata H
    Int J Hematol; 2007 Jul; 86(1):69-71. PubMed ID: 17675270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
    Tsunemine H; Yoshioka S; Sakane E; Akasaka H; Ito K; Kodaka T; Takahashi T
    Gan To Kagaku Ryoho; 2015 May; 42(5):605-7. PubMed ID: 25981655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
    Gao W; An N; Chen SL
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
    van Beurden-Tan CHY; Franken MG; Blommestein HM; Uyl-de Groot CA; Sonneveld P
    J Clin Oncol; 2017 Apr; 35(12):1312-1319. PubMed ID: 28240968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
    Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
    Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
    Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
    Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful treatment with thalidomide-combined therapy in an amyloidosis-complicated multiple myeloma patient refractory to bortezomib, lenalidomide, and pomalidomide].
    Aoki Y; Hayashi T; Ikeda H; Ishida T
    Rinsho Ketsueki; 2018; 59(3):275-280. PubMed ID: 29618684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
    Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
    Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
    Offidani M; Leoni P; Bringhen S; Corvatta L; Larocca A; Gentili S; Oliva S; Polloni C; Galieni P; Catarini M; Alesiani F; Mele A; Brunori M; Blasi N; Ferranti M; Visani G; Boccadoro M; Palumbo A
    Leuk Lymphoma; 2010 Aug; 51(8):1444-9. PubMed ID: 20496998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of thalidomide in previously untreated patients with multiple myeloma.
    Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
    Zomas A; Anagnostopoulos N; Dimopoulos MA
    Bone Marrow Transplant; 2000 Jun; 25(12):1319-20. PubMed ID: 10871741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.